



## Athira Pharma to Participate in Upcoming May Conferences

May 2, 2024

BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- [Athira Pharma, Inc.](#) (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in May.

### **Sidoti May 2024 Virtual Investor Conference**

Format: Company Presentation

Date and Time: Wednesday, May 8, 2024, from 10:45 a.m. - 11:15 a.m. ET

Location: Virtual

### **The Citizens JMP Life Sciences Conference**

Format: Fireside Chat

Date and Time: Monday, May 13, 2024, from 1:30 p.m. - 1:55 p.m. ET

Location: New York Hilton Midtown

Live webcasts of the panel and presentations can be accessed from the Investors section of the Athira website at <https://investors.athira.com/news-and-events/events-and-presentations-investor>. An archived replay of the webcasts will be available for at least 30 days following the event.

### **About Athira Pharma, Inc.**

Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of therapeutic candidates that modulate the neurotrophic HGF system, including fosgonimeton, which is being evaluated for the potential treatment of mild-to-moderate Alzheimer's disease in the Phase 2/3 LIFT-AD trial that is expected to report topline data in the second half of 2024. For more information, visit [www.athira.com](http://www.athira.com). You can also follow Athira on [Facebook](#), [LinkedIn](#) and [@athirapharma](#) on [X](#), (formerly known as [Twitter](#)), and [Instagram](#).

### **Investor Contacts:**

Julie Rathbun

Athira Pharma

[Julie.rathbun@athira.com](mailto:Julie.rathbun@athira.com)

206-769-9219

Anne Marie Fields

Stern Investor Relations

[annemarie.fields@sternjr.com](mailto:annemarie.fields@sternjr.com)

332-213-1956

### **Media Contact:**

Janine Bogris

Inizio Evoke Comms

[Janine.bogris@inizioevoke.com](mailto:Janine.bogris@inizioevoke.com)

201-245-6838